表紙
市場調查報告書

代謝型麩胺酸受體5 (mGluR5/GRM5/GPRC1E/MGLUR5):開發中產品分析

Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 363126
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
代謝型麩胺酸受體5 (mGluR5/GRM5/GPRC1E/MGLUR5):開發中產品分析 Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 76 Pages
簡介

本報告提供全球各國的代謝型麩胺酸受體5 (mGluR5/GRM5/GPRC1E/MGLUR5) 治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

  • 簡介
    • 分析範圍
  • 代謝型麩胺酸受體5 (mGluR5/GRM5/GPRC1E/MGLUR5)的概要
  • 治療藥的開發
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 各大學/研究機關開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • Addex Therapeutics Ltd
    • Confluence Pharmaceuticals LLC
    • Eisai
    • Eli Lilly and Company
    • Heptares Therapeutics Limited
    • Hua Medicine (Shanghai) Ltd.
    • Johnson & Johnson
    • Medgenics, Inc.
    • Merz Pharma GmbH & Co. KgaA
    • Novartis AG
    • 大日本住友製藥
  • 藥物簡介
    • acamprosate calcium
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的發展情形
    • alloswitch-1
    • dipraglurant ER (控制放出)
    • dipraglurant IR (即時放出)
    • DSR-98776
    • fasoracetam
    • GET-73
    • HTL-14242
    • JNJ-46778212
    • LSN-2463359
    • LSN-2814617
    • mavoglurant
    • MRZ-8676
    • 癡呆症的代謝型麩胺酸受體5 (mGlu5) 活性化用小分子
    • 疼痛的mGlu5較量用小分子
    • 神經疾病的mGluR、mGluR6較量用小分子
    • 中樞神經系統 (CNS) 疾病的mGluR5較量用小分子
    • 運動功能障礙的mGluR5較量用小分子
    • 思覺失調症的mGluR5標的小分子
    • VU-0092273
    • VU-0431316
    • VU-0463841
    • VU-0467558
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿 (共15件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2430TDB

Summary:

According to the recently published report 'Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2020'; Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 19 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity.

The report 'Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2020' outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Report covers products from therapy areas Central Nervous System and Genetic Disorders which include indications Anxiety Disorders, Depression, Fragile X Syndrome, Alzheimer's Disease, Autism, Dyskinesia, Major Depressive Disorder, Schizophrenia, Alcohol Addiction, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Dementia, Drug Addiction, Drug-Induced Dyskinesia, Movement Disorders, Neurology, Pain, Parkinson's Disease, Rett Syndrome, Spasmodic Torticollis (Cervical Dystonia) and Substance (Drug) Abuse.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
  • The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview
    • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Bristol-Myers Squibb Co
    • Hua Medicine Shanghai Ltd
    • Laboratorio Farmaceutico CT Srl
    • Lactocore Inc
    • Novartis AG
    • Park Active Molecules
    • Richter Gedeon Nyrt
    • Sosei Heptares
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles
    • alloswitch-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • arbaclofen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Products
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones
    • Featured News & Press Releases
      • Appendix
      • Methodology
      • Coverage
      • Secondary Research
      • Primary Research
      • Expert Panel Validation
      • Contact Us
    • Disclaimer

    List of Tables

    • Number of Products under Development by Stage of Development, H1 2020
    • Number of Products under Development by Therapy Areas, H1 2020
    • Number of Products under Development by Indications, H1 2020
    • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
    • Number of Products under Development by Companies, H1 2020
    • Products under Development by Companies, H1 2020
    • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
    • Number of Products under Investigation by Universities/Institutes, H1 2020
    • Products under Investigation by Universities/Institutes, H1 2020
    • Number of Products by Stage and Mechanism of Actions, H1 2020
    • Number of Products by Stage and Route of Administration, H1 2020
    • Number of Products by Stage and Molecule Type, H1 2020
    • Pipeline by Addex Therapeutics Ltd, H1 2020
    • Pipeline by Bristol-Myers Squibb Co, H1 2020
    • Pipeline by Hua Medicine Shanghai Ltd, H1 2020
    • Pipeline by Laboratorio Farmaceutico CT Srl, H1 2020
    • Pipeline by Lactocore Inc, H1 2020
    • Pipeline by Novartis AG, H1 2020
    • Pipeline by Park Active Molecules, H1 2020
    • Pipeline by Richter Gedeon Nyrt, H1 2020
    • Pipeline by Sosei Heptares, H1 2020
    • Dormant Products, H1 2020
    • Dormant Products, H1 2020 (Contd..1), H1 2020
    • Dormant Products, H1 2020 (Contd..2), H1 2020
    • Discontinued Products, H1 2020
    • Discontinued Products, H1 2020 (Contd..1), H1 2020

    List of Figures

    • Number of Products under Development by Stage of Development, H1 2020
    • Number of Products under Development by Therapy Areas, H1 2020
    • Number of Products under Development by Top 10 Indications, H1 2020
    • Number of Products by Mechanism of Actions, H1 2020
    • Number of Products by Stage and Mechanism of Actions, H1 2020
    • Number of Products by Stage and Route of Administration, H1 2020
    • Number of Products by Molecule Types, H1 2020
    • Number of Products by Stage and Molecule Types, H1 2020